Skip to content
Tech News
← Back to articles

Prime assembly with linear DNA donors enables large genomic insertions

read original get Gene Editing CRISPR Kit → more articles
Why This Matters

This article highlights advancements in prime assembly techniques using linear DNA donors, enabling large genomic insertions with higher efficiency and precision. These developments are significant for the tech industry and consumers as they pave the way for more effective gene therapies, improved disease models, and enhanced genetic research. Ultimately, this progress could lead to transformative medical treatments and innovations in biotechnology.

Key Takeaways

Suzuki, K. et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature 540, 144–149 (2016).

Yamamoto, Y. & Gerbi, S. A. Making ends meet: targeted integration of DNA fragments by genome editing. Chromosoma 127, 405–420 (2018).

Anzalone, A. V. et al. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-01133-w (2021).

Lin, Q. et al. High-efficiency prime editing with optimized, paired pegRNAs in plants. Nat. Biotechnol. 39, 923–927 (2021).

Jiang, T., Zhang, X.-O., Weng, Z. & Xue, W. Deletion and replacement of long genomic sequences using prime editing. Nat. Biotechnol. 40, 227–234 (2022).

Wang, J. et al. Efficient targeted insertion of large DNA fragments without DNA donors. Nat. Methods 19, 331–340 (2022).

Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980–D985 (2014).

Jasin, M. & Haber, J. E. The democratization of gene editing: insights from site-specific cleavage and double-strand break repair. DNA Rep. 44, 6–16 (2016).

Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927–930 (2018).

Ihry, R. J. et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat. Med. 24, 939–946 (2018).

... continue reading